Endpoints News 生物医药· ENDPOINTS·· 2026-10-21AI 评分41
Alcon收购Neurotech;Tezspire最新III期临床试验获胜
Alcon and OpenAI make acquisitions; Tezspire's latest Phase 3 win
AI 导读
瑞士眼科专家Alcon以5.5亿美元首付款收购Neurotech Pharmaceuticals,可能产生额外付款。同时,Tezspire在最新III期临床试验中取得胜利。
正文
Alcon acquires Neurotech: The Swiss eye specialist paid $550 million upfront to acquire Neurotech Pharmaceuticals and could make additional payments if …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news